Testing Fmr1 KO Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127.

Westmark, Pamela R; Garrone, Beatrice; Ombrato, Rosella; Milanese, Claudio; Di Giorgio, Francesco Paolo; Westmark, Cara J

Testing Fmr1 ^KO Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127.

Westmark, Pamela R; Garrone, Beatrice; Ombrato, Rosella; Milanese, Claudio; Di Giorgio, Francesco Paolo; Westmark, Cara J.

Afiliação

Westmark PR; Department of Neurology, University of Wisconsin, Madison, WI, United States.
Garrone B; Angelini Pharma S.p.A., Rome, Italy.
Ombrato R; Angelini Pharma S.p.A., Rome, Italy.
Milanese C; Angelini Pharma S.p.A., Rome, Italy.
Di Giorgio FP; Angelini Pharma S.p.A., Rome, Italy.
Westmark CJ; Department of Neurology, University of Wisconsin, Madison, WI, United States.

Front Mol Neurosci ; 14: 751307, 2021.

Article em En | MEDLINE | ID: mdl-34690696

Palavras-chave

amyloid precursor protein; fragile X syndrome; glycogen synthase kinase; metabotropic glutamate receptor 5; seizure

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Mol Neurosci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google